Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Akorn gets FDA warning letter for Illinois plant

Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.

Read More »

GlaxoSmithKline to look for early-stage assets: CEO

GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.

Read More »

Bristol-Myers to buy Celgene for $74 billion

Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.

Read More »

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

Akorn Inc. said the company’s chief executive officer would retire following the drugmaker’s inability to salvage a takeover deal with Germany’s Fresenius SE.

Read More »

CVS, Aetna win U.S. approval for merger

Pharmacy chain CVS Health Corp. won U.S. antitrust approval for the $69 billion acquisition of health insurer Aetna Inc., the Justice Department said.

Read More »

Bayer Cutting More Than 200 Jobs in San Francisco Bay Area

German company Bayer AG is laying off 227 staffers at the company’s manufacturing plant in Berkeley, California. Most of the cuts took place on October 3, 2018.

Read More »

Pfizer Announces Ian Read’s Replacement and Succession Plan

Pfizer announced the company’s succession plan for when Ian Read steps down as chief executive officer on January 1, 2019.

Read More »

Walgreens to pay $34.5 million to settle U.S. charges of misleading investors

Walgreens Boots Alliance Inc. will pay $34.5 million to settle charges that the company misled investors about the increased risk of missing a key financial goal related to its merger in 2012, the top U.S. securities regulator said.

Read More »

Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic Review

Realm Therapeutics opted to discontinue all drug development programs and is considering a potential sale of the Malvern, Pa.-based company following a clinical trial failure with the atopic dermatitis treatment PR022.

Read More »

Takeda to Move U.S. Headquarters to Boston Area

Takeda Pharmaceutical will shutter the company’s Deerfield, Ill., U.S. headquarters and move the operations to Boston as the company consolidates operations following the $62 billion acquisition of Shire. The Illinois facility employs about 1,000 people.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom